Questran
(Cholestyramine)ApprovedSmall molecule
Cholestyramine is used to lower cholesterol levels in the blood and can also help relieve itching caused by certain liver conditions. It works by binding to cholesterol in your digestive system so your body removes it instead of absorbing it.[2] Questran is currently approved and in use across 13 indications[4].[1]
Questran is one of 257 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
13
Indications
24
Total Trials
6
Active Trials
256
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
259 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Empliciti
Bristol-Myers SquibbPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Vepesid
AAvyxa
Phase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Daratumumab SC
Johnson & JohnsonPhase 3
Velcade
TakedaPhase 3
AZD0120
AstraZenecaPhase 3
G-CSF
AArog Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Familial Hypercholesterolemia2 trials
Multiple Sclerosis2 trials
Hyperthyroidism2 trials
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
Unknown status·—·Phase 3·NCT03303053·135 enrolled
Acceptability2 trials
Multiple Myeloma1 trial
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Active, not recruiting·—·Phase 2·NCT05014646·27 enrolled
15 more indications
Homozygous Familial Hypercholesterolemia1 trial
Renal Impairment1 trial
Female1 trial
Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
Recruiting·—·N/A·NCT05966727·20 enrolled
Short Bowel Syndrome1 trial
Hyperlipidemia1 trial
Advanced Pancreatic Adenocarcinoma1 trial
Environmental Exposure1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
QUESTRAN
NDA NDA016640
Dec 5, 1988
QUESTRAN LIGHT
NDA NDA019669
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Questran drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cholestyramine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details